STOCK TITAN

iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences AI
Rhea-AI Summary

iCAD, a leader in AI-powered breast health solutions, will present at the MedInvest MedTech, AI & Digital Healthcare Conference in San Francisco on June 11-12, 2024. CEO Dana Brown and CFO Eric Lonnqvist will participate in one-on-one meetings with investors. This event underscores iCAD's commitment to leveraging AI in cancer detection and its ongoing engagement with the investment community.

Positive
  • iCAD's participation in a major healthcare conference highlights its industry leadership.
  • Engagement with investors through one-on-one meetings can enhance investor relations and potentially attract new investments.
  • Presence of CEO and CFO at the event shows the company's commitment to transparency and investor communication.
Negative
  • The press release lacks specific financial or clinical data which could provide deeper insights into the company's performance.
  • No new product announcements or major business developments are mentioned, which may be seen as a lack of significant news.

NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today the Company will present at the MedInvest MedTech, AI & Digital Healthcare Conference on June 11-12, 2024 in San Francisco, CA. Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, of iCAD, Inc., will participate in one-on-one meetings with investors at the event.

Investors interested in scheduling time with iCAD are requested to register here: https://www.medinvestconferences.com/register

To register to watch iCAD’s investor presentation please visit: https://goodwinlaw.zoom.us/webinar/register/WN_SxZfCQbGSAqNUcYnJYBuGA#/registration

About iCAD, Inc. 
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com

Forward-Looking Statements 
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

CONTACTS

Media inquiries: pr@icadmed.com
Investor Inquiries: ir@icadmed.com


FAQ

What event will iCAD participate in June 2024?

iCAD will participate in the MedInvest MedTech, AI & Digital Healthcare Conference on June 11-12, 2024.

Who will represent iCAD at the MedInvest Conference?

CEO Dana Brown and CFO Eric Lonnqvist will represent iCAD at the MedInvest MedTech, AI & Digital Healthcare Conference.

Where is the MedInvest MedTech, AI & Digital Healthcare Conference held in 2024?

The MedInvest MedTech, AI & Digital Healthcare Conference will be held in San Francisco, CA.

How can investors schedule meetings with iCAD at the MedInvest Conference?

Investors can schedule meetings with iCAD by registering at the MedInvest conference website.

What is the ticker symbol for iCAD?

The ticker symbol for iCAD is ICAD.

iCAD, Inc.

NASDAQ:ICAD

ICAD Rankings

ICAD Latest News

ICAD Stock Data

36.36M
26.54M
5.63%
26.09%
0.72%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States of America
NASHUA